Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]
Discontinued
Reference number: GID-TAG436
Following on from information provided to NICE by the company in May 2011, the appraisal of Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.